2023
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano J, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte J, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A. PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells. Cancer Research 2023, 83: 2513-2526. PMID: 37311042, DOI: 10.1158/0008-5472.can-22-3023.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLung squamous carcinomaAnti-PD-1 therapyRegulatory T cellsCell lung cancerImmunosuppressive microenvironmentLung cancerImmunotherapy resistanceT cellsWorse progression-free survivalCell death protein 1PTEN lossAnti-TGFβ antibodyConversion of CD4PI3K/AKT/mTOR pathwayProgression-free survivalDeath protein 1Treatment of miceImmunosuppressive tumor microenvironmentPTEN/PI3K/AKT/mTOR pathwayAKT/mTOR pathwayPD-L1TLR agonistsTumor rejectionSquamous carcinoma
2022
Two alternative cell line models for the study of multiorganic metastasis and immunotherapy in Lung Squamous Cell Carcinoma
Valencia K, Sainz C, Bértolo C, de Biurrun G, Agorreta J, Azpilikueta A, Larrayoz MJ, Bosco G, Zandueta C, Redrado M, Redín E, Exposito F, Serrano D, Echepare M, Ajona D, Melero I, Pio R, Thomas R, Calvo A, Montuenga LM. Two alternative cell line models for the study of multiorganic metastasis and immunotherapy in Lung Squamous Cell Carcinoma. Disease Models & Mechanisms 2022, 15: dmm049137. PMID: 34870316, PMCID: PMC8822220, DOI: 10.1242/dmm.049137.Peer-Reviewed Original ResearchConceptsLung squamous cell carcinomaSquamous cell carcinomaLUSC cell linesCell carcinomaCell linesHuman squamous cell carcinomaImmune checkpoint inhibitionAdequate mouse modelsCell line modelsCheckpoint inhibitionImmune landscapeAdrenal glandJ miceMouse modelHuman subtypesMetastatic potentialTumor cell linesCarcinomaRNA sequencingRemarkable heterogeneityHuman diseasesTranscriptomic patternsImmunotherapyMetastasisChloroethylurea
2016
Development of biological tools to assess the role of TMPRSS4 and identification of novel tumor types with high expression of this prometastatic protein.
Villalba M, Lopez L, Redrado M, Ruiz T, de Aberasturi AL, de la Roja N, Garcia D, Exposito F, de Andrea C, Alvarez-Fernandez E, Montuenga L, Rueda P, Rodriguez MJ, Calvo A. Development of biological tools to assess the role of TMPRSS4 and identification of novel tumor types with high expression of this prometastatic protein. Histology And Histopathology 2016, 32: 929-940. PMID: 27995596, DOI: 10.14670/hh-11-857.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Squamous CellEscherichia coliLung NeoplasmsMembrane ProteinsRecombinant ProteinsSerine EndopeptidasesTissue Array AnalysisConceptsTissue microarrayTMPRSS4 protein expressionProtein expressionLarge cell carcinomaNovel tumor typesCancer tissue microarraySquamous carcinomaPoor prognosisCell carcinomaAggressive tumorsCancer deathLung cancerMetastatic spreadDifferent tissue microarraysClinical valueTherapeutic targetTumor typesClinical settingRabbit polyclonal antiserumCancer typesType II serine proteaseHigh expressionTMPRSS4CarcinomaCancer